STOCK TITAN
  1. Home
  2. News
  3. SLDB

Solid Biosciences Inc - SLDB STOCK NEWS

Welcome to our dedicated news page for Solid Biosciences (Ticker: SLDB), a resource for investors and traders seeking the latest updates and insights on Solid Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Solid Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Solid Biosciences's position in the market.

News
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Solid Biosciences Inc. grants inducement awards to two new employees as part of its 2024 Inducement Stock Incentive Plan. The awards consist of 17,090 shares of common stock, vesting in four equal installments annually over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.12%
Tags
none
-
News
Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
Rhea-AI Summary
Solid Biosciences Inc. (SLDB) receives Rare Pediatric Disease Designation from the FDA for SGT-003, a gene therapy candidate for Duchenne muscular dystrophy. The company plans to initiate site activations in April 2024 and start patient dosing in Q2 2024. The Phase 1/2 trial, INSPIRE Duchenne, aims to assess the safety and tolerability of SGT-003 in pediatric patients with DMD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.61%
Tags
none
-
News
Solid Biosciences to Participate at Cantor’s Virtual Muscular Dystrophy Symposium
Rhea-AI Summary
Solid Biosciences Inc. to present at Cantor's Virtual Muscular Dystrophy Symposium. Bo Cumbo, CEO, and Gabriel Brooks, CMO, will discuss precision genetic medicines for neuromuscular and cardiac diseases on April 2, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.01%
Tags
conferences
News
Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results
Rhea-AI Summary
Solid Biosciences Inc. ends 2023 with $123.6 million in cash and investments, with a cash runway anticipated into 2026. The company obtained FDA clearance, Fast Track Designation, and Orphan Drug Designation for Duchenne gene therapy candidate SGT-003. Solid also entered a licensing agreement for AAV-SLB101 capsid use.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.28%
Tags
earnings
-
News
Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD
Rhea-AI Summary
Solid Biosciences (SLDB) collaborates with Armatus Bio for FSHD treatment using AAV-SLB101 capsid. The agreement includes upfront payment, milestone payments, and royalties. AAV-SLB101 shows enhanced biodistribution and muscle cell expression in preclinical studies. Armatus will develop and commercialize ARM-201, a potential FSHD therapeutic, utilizing AAV-SLB101.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.86%
Tags
none
-
News
Solid Biosciences to Participate at Upcoming Investor Conferences
Rhea-AI Summary
Solid Biosciences Inc. (SLDB) will be participating in the Leerink Partners Global Biopharma Conference and Barclays 26th Annual Global Healthcare Conference in Miami, FL. Bo Cumbo, the President and CEO, will present on March 13, 2024, at 1:35 pm ET. Institutional investors can arrange meetings with management through Leerink or Barclays representatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
conferences
News
Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
Rhea-AI Summary
Solid Biosciences Inc. has been granted orphan drug designation (ODD) from the U.S. Food and Drug Administration for SGT-003, their next-generation Duchenne muscular dystrophy gene therapy candidate. The company is preparing for a Phase 1/2 clinical trial and expects patient dosing to begin in mid-to-late Q1 2024. The therapy has unique attributes that may yield more potent transduction and a microdystrophin capable of addressing muscle resiliency.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.76%
Tags
clinical trial
-
News
Solid Biosciences Announces $109 Million Private Placement
Rhea-AI Summary
Solid Biosciences Inc. (SLDB) announced a $108.9 million private placement with institutional accredited investors for developing precision genetic medicines for neuromuscular and cardiac diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.59%
Tags
none
-
News
Solid Biosciences to Participate at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Solid Biosciences Inc. (Nasdaq: SLDB) announced that Bo Cumbo, President and CEO, will present at the J.P Morgan Healthcare Conference on January 11, 2024. The company is developing precision genetic medicines for neuromuscular and cardiac diseases. A live webcast of the presentation will be available on the Company website. Institutional investors interested in meeting management during the conference may reach out to their J.P. Morgan representatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.34%
Tags
conferences
News
Solid Biosciences Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Gene Therapy SGT-003
Rhea-AI Summary
Solid Biosciences Inc. (Nasdaq: SLDB) has received FDA Fast Track Designation for SGT-003, its next-generation Duchenne muscular dystrophy gene therapy candidate. The company aims to rapidly develop this potentially life-changing therapy to address the unmet needs of the Duchenne community. IND clearance for SGT-003 was received in November 2023, with a planned Phase 1/2 trial to determine safety and tolerability in pediatric patients. Solid Biosciences looks forward to continuing its partnership with the FDA to ensure the collection of data needed to support future marketing authorization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
68.42%
Tags
clinical trial
Stock SLDB logo
Solid Biosciences Inc

Nasdaq:SLDB

SLDB Rankings

#3308 Ranked by Market Cap
#5151 Ranked by Stock Gains
N/A Ranked by Dividends

SLDB Stock Data

391.54M
18.01M
0.79%
75.88%
2.44%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Charlestown

About SLDB

solid biosciences (solid) is a cambridge, ma based biotech company singularly focused on developing treatments and cures for duchenne muscular dystrophy (dmd). solid combines sharp commercial focus with world-class science to advance promising therapies and is positioned to catalyze therapeutic development across all aspects of the disease. condition-focused, our mandate is comprehensive; improving daily life for patients and attacking the roots of dmd.